A Randomized, Placebo-controlled Trial of Digestive Enzymes in Children with Autism Spectrum Disorders
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Objective: There is growing evidence for a gut-brain connection associated with autism spectrum disorders (ASDs). This suggests a potential benefit from introduced digestive enzymes for children with ASD. Methods: We performed a double-blind, randomized clinical trial on 101 children with ASD (82 boys and 19 girls) aged from 3 to 9 years. ASD patients were diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders 4th edition, text revision (DSM-IV-TR) diagnostic criteria. Structured interviews of at least one hour each both with the parents and the child were performed. Later on, another two hours-session was conducted applying the Childhood Autism Rating Scale (CARS). ASD patients were randomized to receive digestive enzymes or placebo. Results: The ASD group receiving digestive enzyme therapy for 3 months had significant improvement in emotional response, general impression autistic score, general behavior and gastrointestinal symptoms. Our study demonstrated the usefulness of digestive enzyme in our population of ASD patients. Conclusion: Digestive enzymes are inexpensive, readily available, have an excellent safety profile, and have mildly beneficial effects in ASD patients. Depending on the parameter measured in our study, we propose digestive enzymes for managing symptoms of ASD. Digestive enzyme therapy may be a possible option in treatment protocols for ASD in the future.
Abstract
Objective: There is growing evidence for a gut-brain connection associated with autism spectrum disorders (ASDs). This suggests a potential benefit from introduced digestive enzymes for children with ASD. Methods: We performed a double-blind, randomized clinical trial on 101 children with ASD (82 boys and 19 girls) aged from 3 to 9 years. ASD patients were diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders 4th edition, text revision (DSM-IV-TR) diagnostic criteria. Structured interviews of at least one hour each both with the parents and the child were performed. Later on, another two hours-session was conducted applying the Childhood Autism Rating Scale (CARS). ASD patients were randomized to receive digestive enzymes or placebo. Results: The ASD group receiving digestive enzyme therapy for 3 months had significant improvement in emotional response, general impression autistic score, general behavior and gastrointestinal symptoms. Our study demonstrated the usefulness of digestive enzyme in our population of ASD patients. Conclusion: Digestive enzymes are inexpensive, readily available, have an excellent safety profile, and have mildly beneficial effects in ASD patients. Depending on the parameter measured in our study, we propose digestive enzymes for managing symptoms of ASD. Digestive enzyme therapy may be a possible option in treatment protocols for ASD in the future.
참고문헌 (15)
- Munasinghe SA., "Digestive enzyme supplementation for autism spectrum disorders : a doubleblind randomized controlled trial", J Autism Dev Disord, 40, pp.1131~1138 (2010)
- Saad K., "Autistic symptoms in late diagnosed phenylketonuric children in upper Egypt", J Neurol Res, 3, pp.51~55 (2013)
- Parmeggiani A., "Comprehensive guide to autism. New York:Springer Science plus Business Media", pp.2035~2046 (2014), Springer Science plus Business Media
- Adams JB., "Effect of a vitamin", mineral supplement on children and adults with autism, 2011, pp.11, 111~
- Lofthouse N., "A review of complementary and alternative treatments for autism spectrum disorders", Autism Res Treat, 2012, pp.870391~ (2012)
- Brudnak MA., "Enzyme-based therapy for autism spectrum disorders-is it worth another look?", Med Hypotheses, 58, pp.422~428 (2002)
- American Psychiatric Association., "Diagnostic and statistical manual of mental disorders : DSM-IV-TR" (2000), American Psychiatric Association
- Rellini E., "Childhood Autism Rating Scale(CARS)and Autism Behavior Checklist(ABC)correspondence and conflicts with DSM-IV criteria in diagnosis of autism", J Autism Dev Disord, 34, pp.703~708 (2004)
- Levy SE., "Children with autistic spectrum disorders. I : comparison of placebo and single dose of human synthetic secretin", Arch Dis Child, 88, pp.731~736 (2003)
- Rawlings ND., "Families of cysteine peptidases", Methods Enzymol, 244, pp.461~486 (1994)
- "Summary of dietary, nutritional, and medical treatments for autism based on over 150 published research studies" (2013)[URL]
- Buie T., "Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report", Pediatrics, 125(Suppl 1), pp.S1~S18 (2010)
- Horvath K., "Gastrointestinal abnormalities in children with autistic disorder", J Pediatr, 135, pp.559~563 (1999)
- Williams BL., "Impaired carbohydrate digestion and transport and mucosal dysbiosis in the intestines of children with autism and gastrointestinal disturbances", PLoS One, 6, pp.e24585~ (2011)
- Kushak RI., "Intestinal disaccharidase activity in patients with autism : effect of age, gender, and intestinal inflammation", Autism, 15, pp.285~294 (2011)